Rallybio EPS RLYB
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Sep 30, 2026
- $4.56
- Latest quarter, Q3 FY26
- −$0.48
- −117% on a year earlier
- Fiscal year 2025
- −$1.64
Rallybio's earnings per share was $4.56 over the twelve months to Sep 30, 2026.
In its latest quarter, Q3 FY26, it was −$0.48, down 117% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.64 | n/a |
| FY2024 | −$10.80 | n/a |
| FY2023 | −$14.72 | n/a |
| FY2022 | −$16.88 | n/a |
| FY2021 | −$14.96 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.48 | −117% | $4.56 | |
| Q2 FY26 | $7.53 | n/a | $7.88 | |
| Q1 FY26 | −$1.46 | n/a | −$1.41 | |
| Q4 FY25 | −$1.03 | n/a | −$1.64 | |
| Q3 FY25 | $2.84 | n/a | −$2.61 | |
| Q2 FY25 | −$1.76 | n/a | −$7.53 | |
| Q1 FY25 | −$1.69 | n/a | −$8.73 | |
| Q4 FY24 | −$2.00 | n/a | −$10.80 | |
| Q3 FY24 | −$2.08 | n/a | −$12.80 | |
| Q2 FY24 | −$2.96 | n/a | −$14.32 | |
| Q1 FY24 | −$3.76 | n/a | −$15.04 | |
| Q4 FY23 | −$4.00 | n/a | −$14.72 |
Against its peers
Companies in Drug Manufacturers - General nearest Rallybio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RLYBRallybio | $4.56 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| CRMDCorMedix | $2.13 | +184% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Rallybio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.